-

Calyxo, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, announced today that Joe Catanese, Ph.D., Chief Executive Officer of Calyxo will present at the J.P. Morgan 44th Annual Healthcare Conference on Monday, January 12, 2026, at 8:30 AM PT in San Francisco, CA.

“Being invited to present at the J.P. Morgan Healthcare Conference for the first time is a meaningful milestone,” said Joe Catanese. “We’ve made significant progress expanding adoption of the CVAC System and advancing our clinical evidence"

Share

“Being invited to present at the J.P. Morgan Healthcare Conference for the first time is a meaningful milestone for Calyxo and reflects the strong momentum we’ve built across our business,” said Joe Catanese. “We’ve made significant progress expanding adoption of the CVAC System, advancing our clinical evidence, and scaling our commercial footprint. I look forward to sharing how our continued focus on innovation and clinical evidence is driving growth and improving care for patients with kidney stone disease.”

About Kidney Stones

According to the American Urological Association, approximately 10% of people in the U.S. will have a kidney stone at some point in their lives. Kidney stone disease is a painful condition that can result in significant healthcare costs (Current Urology Reports estimates $4.1 billion in annual direct treatment costs by 2030).

About the CVAC System

The CVAC System was FDA-cleared in 2024 and enables a minimally invasive approach for kidney stone clearance. It is an all-in-one solution designed to efficiently and effectively remove kidney stones. It uses irrigation and vacuum aspiration to continuously clear stone fragments during and after laser lithotripsy, enabling physicians to achieve a stone-free outcome.

About Calyxo, Inc.

Calyxo, Inc. is an innovation-driven medical device company focused on improving care for patients with kidney stones by delivering paradigm-shifting solutions that enable urologists to safely, effectively and efficiently achieve unrivaled clinical outcomes. Learn more at calyxoinc.com.

“CVAC” and “Calyxo” are registered trademarks of Calyxo, Inc.

Contacts

Media Contact:
Alyssa Paldo
Alyssa.paldo@finnpartners.com
M: +1 847 791 8085

Industry:

Calyxo, Inc.

Release Versions
English

Contacts

Media Contact:
Alyssa Paldo
Alyssa.paldo@finnpartners.com
M: +1 847 791 8085

More News From Calyxo, Inc.

Six New EAU 2026 Abstracts Show CVAC System Delivers Consistently Low Residual Stone Volume, Greater Procedural Efficiency, and Reduced Downstream Clinical and Economic Burden

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company revolutionizing kidney stone treatment, today announced the presentation of six new abstracts at the 41st Annual European Association of Urology Annual Congress in London (EAU26). The data collectively differentiate the CVAC System as a unique, high-performance aspiration system that delivers superior stone clearance1-5, greater procedural efficiency3, and significant reductions in long-term clinical and economic burden...

Newly Published Evidence Show Calyxo’s CVAC System Significantly Reduces Residual Stone Volume and Unplanned Health Events

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company revolutionizing kidney stone treatment, today announced the peer-reviewed publication of results from the CLEARANCE study and ASPIRE randomized controlled trial evaluating the Steerable Ureteral Renal Evacuation (SURE) procedure with the CVAC System. Across both studies, the CVAC System demonstrated consistently high stone clearance and low residual stone volume. Topline CLEARANCE results show 96% mean clearance and mea...

Calyxo Expands Board of Directors as Number of Patients Treated with its CVAC® System Crosses 20,000 Milestone

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, marked key milestones as adoption of the steerable ureteroscopic renal evacuation (SURE) procedure using the company’s CVAC System continues to accelerate. The company has appointed Dana G. Mead, Jr. to its board of directors, and it has reached more than 20,000 patients treated to date with the CVAC System, further establishing the technology as a new standard...
Back to Newsroom